نتایج جستجو برای: hypercvad

تعداد نتایج: 72  

Journal: :Haematologica 2013
Reyes Arranz Ana García-Noblejas Carlos Grande Jimena Cannata-Ortiz José J Sánchez José-Antonio García-Marco Concepción Aláez Javier Pérez-Calvo Pilar Martínez-Sánchez Blanca Sánchez-González Miguel-Angel Canales Eulogio Conde Alejandro Martín Eva Arranz María-José Terol Antonio Salar Dolores Caballero

UNLABELLED The prognosis for fit patients with mantle cell lymphoma has improved with intensive strategies. Currently, the role of maintenance/consolidation approaches is being tested as relapses continue to appear. In this trial we evaluated the feasibility, safety and efficacy of rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine followed by consolidation with (90)Y-ibritu...

2011
Alexander Pham Amir Steinberg Brian Kwok Angela Lopez Stephen Lim Michael Lill

We present the 16th reported case of Acute Lymphoblastic Leukemia (ALL) with involvement in the bladder. Our patient was a 22 year-old man with T-cell ALL with a mediastinal mass. He received hyperfractionated cyclophos-phamide, vincristine, doxorubicin, dexamethasone (HyperCVAD) with mediastinal radiation. Prior to starting maintenance, he relapsed in the bladder and marrow. He received a nela...

2017
Hae Su Kim Hee-Jin Kim Sun-Hee Kim Joon Young Choi Young Hyeh Ko Won Seog Kim Chul Won Jung Seok Jin Kim

BACKGROUND/AIMS Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy that typically presents in the form of skin manifestations with or without lymph node and bone marrow involvement. Given its rarity and recent recognition as a distinct pathological entity, no standard of treatment exists for this aggressive disease and its prognosis is particularly dismal. M...

Journal: :Clinical advances in hematology & oncology : H&O 2011
Jennifer M Duff Michelle L Rossi Jason Fromm Jack W Hsu

Blastic natural killer (NK) cell neoplasms are rare, highly aggressive malignancies with a poor prognosis. They have a predilection for the skin, and disseminate rapidly into the blood, bone marrow, lymph nodes, and extranodal organs.1 Because of their rarity, there is no standard treatment. Chemotherapy alone does not result in long-term remissions2; therefore, stem cell transplantation is ess...

Journal: :Oncology 2003
John Kauh Said M Baidas Metin Ozdemirli Bruce D Cheson

Mantle cell lymphoma (MCL) accounts for approximately 6% of non-Hodgkin's lymphomas. Patients usually present with advanced disease, with a tendency for extranodal involvement. MCL is an aggressive lymphoma with moderate chemosensitivity, but it remains one of the most difficult therapeutic challenges. Complete response rates to chemotherapy range from 20% to 40%, with median survivals of 2 1/2...

Journal: :Srpski arhiv za celokupno lekarstvo 2015
Natasa Colović Andrija Bogdanović Marijana Virijević Ana Vidović Dragica Tomin

INTRODUCTION In patients with acute leukemias hemorrhage is the most frequent problem. Vein thrombotic events may appear rarely but arterial thromboses are exceptionally rare. We present a patient with acute leukemia and bilateral deep leg vein thrombosis who developed an acute myocardial infarction (AMI) during induction chemotherapy. The etiology and treatment of AMI in patients with acute le...

Journal: :Blood 1995
J Cortes S M O'Brien S Pierce M J Keating E J Freireich H M Kantarjian

Although central nervous system (CNS) leukemic relapse is frequent in adult acute lymphocytic leukemia (ALL), the need for prophylaxis in different risk groups for CNS relapse, the value of high-dose systemic and intrathecal (IT) chemotherapy, and the timing of prophylaxis are not well defined. This analysis was conducted to investigate these questions and to assess the value of a risk-oriented...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید